Loading...
Loading...
APTO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 11.7M |
| Operating I/L | -11.4M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.2M |
| Pretax | -11.4M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -11.4M |
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing personalized therapies for oncology. The company's clinical programs include APTO-253 and HM43239, both in Phase 1/2 clinical trials for treating relapsed or refractory blood cancers, particularly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Additionally, Aptose is developing luxeptinib for B-cell malignancies and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.
